ALNYLAM PHARMACEUTICALS, INC. Intellectual Property Contracts & Agreements
5 Contracts & Agreements
- License Agreements (5 contracts)
- Amended and Restated ALN-AT3 Global License Terms entered into as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)
- Exclusive License Agreement entered into as of January 6, 2018 by and between the Registrant and Genzyme Corporation (Filed With SEC on May 4, 2018)
- ALN-AT3 Global License Terms entered into as of January 6, 2018 by and between the Registrant and Genzyme Corporation (Filed With SEC on May 4, 2018)
- EXCLUSIVE LICENSE AGREEMENT FOR TUSCHL II UNITED STATES PATENTS AND PATENT APPLICATIONS (Filed With SEC on October 2, 2015)
- Ex-10.19 Co-exclusive License Agreement (Filed With SEC on April 29, 2004)
